Home
News
Create
Screeners
Insights
Remus Pharmaceuticals
680.
50
-9.75
(-1.41%)
Market Cap
₹801.90 Cr
PE Ratio
17.37
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-1.41%
1M
-12.07%
6M
-3.45%
1Y
-65.25%
5Y
-71.26%
View Company Insights
Latest news about Remus Pharmaceuticals
Remus Pharmaceuticals FY26 net profit rises 20% to ₹46 crore
May 29, 2026
Remus Pharmaceuticals reported a 20% YoY rise in FY26 net profit to ₹46 crore, with revenue growing 38% to ₹854 crore. The B2C segment's revenue contribution increased to 14%, driven by new product launches in Latin America. The company plans to expand its B2C segment further in FY27 and has initiated filings for semaglutide in emerging markets.
Remus FY26 PAT rises 20% to ₹46.17 Cr, declares dividend
May 22, 2026
Remus Pharmaceuticals posts FY26 earnings call audio
May 22, 2026
Remus Pharmaceuticals appoints Tapan Shah as Secretarial Auditor
May 21, 2026
Remus Pharmaceuticals appoints Sharp & Tannan as Internal Auditor
May 21, 2026
More news about Remus Pharmaceuticals
10
Nov 25
Remus Pharmaceuticals Posts 34% Surge in H1 Net Profit, Revenue Soars 47%
Remus Pharmaceuticals, a key player in the Indian pharmaceutical sector, has announced robust financial results for the first half of the fiscal year. The company's consolidated revenue increased by 47% to ₹4,000.00 crore, while net profit rose by 34% to ₹175.00 crore compared to the same period last year. EBITDA grew by 27% to ₹269.00 crore. However, the EBITDA margin contracted by 110 basis points to 6.70% from 7.80% in the previous year.
Remus Pharmaceuticals
680.
50
-
9.
75
(-
1.
41
%)
1 Year Returns:
-65.25%
Industry Peers
Sun Pharmaceutical
1,786.40
(+
0.
42
%)
Divis Laboratories
6,638.50
(-
1.
70
%)
Torrent Pharmaceuticals
4,463.70
(-
0.
21
%)
Cipla
1,377.00
(+
0.
04
%)
Zydus Life Science
1,098.30
(-
0.
66
%)
Dr Reddys Laboratories
1,271.70
(+
0.
25
%)
Lupin
2,247.20
(-
0.
75
%)
Mankind Pharma
2,376.20
(-
0.
62
%)
Aurobindo Pharma
1,453.60
(+
0.
32
%)
Laurus Labs
1,385.70
(-
2.
72
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar